Details of the Drug

General Information of Drug (ID: DMU7YEL)

• Drug Name: Sufentanil
• Synonyms: Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide

Indication

Disease Entry	ICD 11	Status	REF
Analgesia	MB40.8	Approved	[1]

• Therapeutic Class: Anesthetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 386.6
  Topological Polar Surface Area (xlogp); 4
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [2]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 20% [2]
  Clearance: The total plasma clearance of drug is 917 L/min [4]
  Elimination: Approximately 80% of the administered dose is excreted within 24 hours and only 2% of the dose is eliminated as unchanged drug [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 164 minutes (in adults) [5]
  Metabolism: The drug is metabolized via the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.06467 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.075% [7]
  Vd: The volume of distribution (Vd) of drug is 14 L [4]
• Chemical Identifiers:
  Formula: C22H30N2O2S
  IUPAC Name: N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
  Canonical SMILES: CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
  InChI: InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
  InChIKey: GGCSSNBKKAUURC-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 41693
  ChEBI ID: CHEBI:9316
  CAS Number: 56030-54-7
  DrugBank ID: DB00708
  TTD ID: D0D8DD
  VARIDT ID: DR00602
  INTEDE ID: DR1508

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Antagonist	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sufentanil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Sufentanil caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[29]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Sufentanil due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[30]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Sufentanil and Scopolamine.	Addictive disorder [6C50-6C5Z]	[31]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Sufentanil due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[30]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Sufentanil and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[32]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Sufentanil and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[33]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Sufentanil caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[34]
Desipramine	DMT2FDC	Moderate	Additive serotonergic effects by the combination of Sufentanil and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[35]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Sufentanil caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Sufentanil caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[34]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Sufentanil caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[34]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Sufentanil and Cariprazine.	Bipolar disorder [6A60]	[33]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Sufentanil caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[37]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Sufentanil caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Sufentanil caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Sufentanil caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Sufentanil and Levomilnacipran.	Chronic pain [MG30]	[40]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Sufentanil and Olopatadine.	Conjunctiva disorder [9A60]	[41]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Sufentanil and Propofol.	Corneal disease [9A76-9A78]	[42]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Sufentanil caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[43]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Sufentanil and Ethanol.	Cystitis [GC00]	[44]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Sufentanil caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[45]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Sufentanil and Sertraline.	Depression [6A70-6A7Z]	[40]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Sufentanil and Trimipramine.	Depression [6A70-6A7Z]	[35]
Cyclobenzaprine	DM1YBRM	Major	Additive CNS depression effects by the combination of Sufentanil and Cyclobenzaprine.	Depression [6A70-6A7Z]	[46]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Sufentanil and Nefazodone.	Depression [6A70-6A7Z]	[40]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Sufentanil and Paroxetine.	Depression [6A70-6A7Z]	[40]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Sufentanil and Vortioxetine.	Depression [6A70-6A7Z]	[40]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Sufentanil and Milnacipran.	Depression [6A70-6A7Z]	[40]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Sufentanil and Escitalopram.	Depression [6A70-6A7Z]	[40]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Sufentanil and Desvenlafaxine.	Depression [6A70-6A7Z]	[40]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Sufentanil and OPC-34712.	Depression [6A70-6A7Z]	[33]
Clomipramine	DMINRKW	Moderate	Additive serotonergic effects by the combination of Sufentanil and Clomipramine.	Depression [6A70-6A7Z]	[35]
Doxepin	DMPI98T	Moderate	Additive serotonergic effects by the combination of Sufentanil and Doxepin.	Depression [6A70-6A7Z]	[35]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Sufentanil and Maprotiline.	Depression [6A70-6A7Z]	[35]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Sufentanil and Esketamine.	Depression [6A70-6A7Z]	[43]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Sufentanil and Mepenzolate.	Digestive system disease [DE2Z]	[31]
Oxybutynine	DMJPBAX	Moderate	Additive CNS depression effects by the combination of Sufentanil and Oxybutynine.	Discovery agent [N.A.]	[31]
Primidone	DM0WX6I	Major	Additive CNS depression effects by the combination of Sufentanil and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[33]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Sufentanil and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[47]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Sufentanil caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Sufentanil and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[33]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Sufentanil and Dantrolene.	Fever [MG26]	[33]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Sufentanil and Tolterodine.	Functional bladder disorder [GC50]	[31]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Sufentanil caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[34]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Sufentanil caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[34]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Sufentanil and Propantheline.	Gastric ulcer [DA60]	[49]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Sufentanil caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Sufentanil caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Sufentanil caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Sufentanil caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Sufentanil caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Sufentanil caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Sufentanil caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[34]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Sufentanil caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[51]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Sufentanil and Suvorexant.	Insomnia [7A00-7A0Z]	[33]
Amobarbital	DM0GQ8N	Major	Additive CNS depression effects by the combination of Sufentanil and Amobarbital.	Insomnia [7A00-7A0Z]	[33]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Sufentanil and Ramelteon.	Insomnia [7A00-7A0Z]	[33]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Sufentanil and Zaleplon.	Insomnia [7A00-7A0Z]	[33]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Sufentanil and Propiomazine.	Insomnia [7A00-7A0Z]	[33]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Sufentanil and Tasimelteon.	Insomnia [7A00-7A0Z]	[33]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Sufentanil and Paraldehyde.	Insomnia [7A00-7A0Z]	[33]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Sufentanil and ITI-007.	Insomnia [7A00-7A0Z]	[33]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Sufentanil and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[52]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Sufentanil and Clidinium.	Irritable bowel syndrome [DD91]	[31]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Sufentanil and Dicyclomine.	Irritable bowel syndrome [DD91]	[31]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Sufentanil caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[30]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Sufentanil caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Sufentanil caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Sufentanil caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[54]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Sufentanil caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[30]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Sufentanil caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[55]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Sufentanil caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[34]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Sufentanil caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[56]
LGX818	DMNQXV8	Moderate	Increased metabolism of Sufentanil caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[57]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Sufentanil and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[58]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Sufentanil caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[59]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Sufentanil and Flibanserin.	Mood disorder [6A60-6E23]	[60]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Sufentanil and Thalidomide.	Multiple myeloma [2A83]	[61]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Sufentanil due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[62]
Modafinil	DMYILBE	Minor	Increased metabolism of Sufentanil caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[63]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Sufentanil when combined with Metoclopramide.	Nausea/vomiting [MD90]	[64]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Sufentanil and Granisetron.	Nausea/vomiting [MD90]	[65]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Sufentanil and Dolasetron.	Nausea/vomiting [MD90]	[65]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Sufentanil and Ondansetron.	Nausea/vomiting [MD90]	[65]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Sufentanil and Bupropion.	Nicotine use disorder [6C4A]	[66]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Sufentanil and Sibutramine.	Obesity [5B80-5B81]	[67]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Sufentanil and Lorcaserin.	Obesity [5B80-5B81]	[68]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Sufentanil and Dexfenfluramine.	Obesity [5B80-5B81]	[40]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Sufentanil and Apraclonidine.	Optic nerve disorder [9C40]	[69]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Sufentanil caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[43]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Sufentanil caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[70]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Sufentanil and Flavoxate.	Pain [MG30-MG3Z]	[31]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Sufentanil and Biperiden.	Parkinsonism [8A00]	[71]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Sufentanil and Pimavanserin.	Parkinsonism [8A00]	[33]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Sufentanil and Orphenadrine.	Parkinsonism [8A00]	[33]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Sufentanil caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[72]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Sufentanil and Methylscopolamine.	Peptic ulcer [DA61]	[31]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Sufentanil caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[73]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Sufentanil caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[34]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Sufentanil due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[30]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Sufentanil due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[30]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Sufentanil and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[74]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Sufentanil due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Sufentanil due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Sufentanil due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Sufentanil due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Sufentanil due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[30]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Sufentanil and Quetiapine.	Schizophrenia [6A20]	[75]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Sufentanil and Mesoridazine.	Schizophrenia [6A20]	[76]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Sufentanil and Aripiprazole.	Schizophrenia [6A20]	[33]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Sufentanil and Iloperidone.	Schizophrenia [6A20]	[33]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Sufentanil and Paliperidone.	Schizophrenia [6A20]	[33]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Sufentanil and Perphenazine.	Schizophrenia [6A20]	[33]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Sufentanil and Molindone.	Schizophrenia [6A20]	[33]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Sufentanil and Thiothixene.	Schizophrenia [6A20]	[76]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Sufentanil and Trifluoperazine.	Schizophrenia [6A20]	[33]
Risperidone	DMN6DXL	Major	Additive CNS depression effects by the combination of Sufentanil and Risperidone.	Schizophrenia [6A20]	[33]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Sufentanil and Asenapine.	Schizophrenia [6A20]	[33]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Sufentanil and Pimozide.	Schizophrenia [6A20]	[33]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Sufentanil caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[30]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Sufentanil caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[43]
Armodafinil	DMGB035	Minor	Increased metabolism of Sufentanil caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[63]
LEE011	DMMX75K	Moderate	Decreased metabolism of Sufentanil caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[77]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Sufentanil caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[30]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Sufentanil due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[62]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Sufentanil and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[74]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Sufentanil and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[74]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Svetel M, Tomic A, Kresojevic N, Kostic V: Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):353-360. doi: 10.1080/17425255.2018.1430138. Epub 2018 Jan 24.
• [3] BDDCS applied to over 900 drugs
• [4] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [5] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
• [9] Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
• [10] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [11] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [12] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [13] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [14] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [15] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [16] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [17] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [18] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [19] Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
• [20] The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
• [22] Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
• [23] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [24] Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
• [25] Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
• [26] Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
• [27] Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
• [28] Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
• [29] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [30] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [31] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [32] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [33] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [34] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
• [35] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [36] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [37] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [38] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [39] Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [40] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [41] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [42] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [43] Cerner Multum, Inc. "Australian Product Information.".
• [44] Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
• [45] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [46] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [47] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
• [48] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [49] Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
• [50] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [51] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [52] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [53] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [54] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [55] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [56] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [57] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [58] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [59] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [60] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [61] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [62] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [63] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [64] Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [65] Canadian Pharmacists Association.
• [66] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [67] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [68] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [69] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [70] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [71] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
• [72] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [73] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [74] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [75] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [76] Cerner Multum, Inc. "Canadian Product Information.".
• [77] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]